ライフサイエンスコーパス: atorvastatin

1 aseline and after 12 weeks of treatment with atorvastatin.

2 iltration rate <60 mL/min/1.73 m2) receiving atorvastatin.

3 transcellular biosynthesis and increased by atorvastatin.

4 and human liver cirrhosis and was blunted by atorvastatin.

5 ibed antihyperlipidemic drugs, ezetimibe and atorvastatin.

6 and identified synergy between rapamycin and atorvastatin.

7 ng therapy with fluvastatin, pravastatin, or atorvastatin.

8 onate largely reduced the negative effect of atorvastatin.

9 e increased 20.8+/-141.1 U/L (P<0.0001) with atorvastatin.

10 ; P = 0.01) compared with those who received atorvastatin.

11 lar events in patients treated with low-dose atorvastatin.

12 en reversed by 3-week treatment with 5 mg/kg atorvastatin.

13 nucleus, increased the inhibitory effect of atorvastatin.

14 locumab by a mechanism distinct from that of atorvastatin.

15 -density lipoprotein cholesterol levels with atorvastatin.

16 statins, the primary metabolites of the drug atorvastatin.

17 inistration of 2 clinically relevant statins-atorvastatin (0.2 mg/kg) or pravastatin (0.2 mg/kg)-to m

18 Considering the type of statin used, atorvastatin (0.51; 0.41-0.64), pravastatin (0.40; 0.28-

19 andomized 108 C57Bl/6J mice to receive daily atorvastatin 1.14 mg/kg or PBS (control) starting 7 days

20 14.42% [8.7% to 19.8%]; p < 0.001), but not atorvastatin 10 mg (% reduction: 4.2% [-2.3% to 10.4%];

21 additional relative reductions in TBR versus atorvastatin 10 mg (10.6% [2.2% to 18.3%]; p = 0.01) at

22 as early as 4 weeks after randomization with atorvastatin 10 mg (6.4% reduction, p < 0.05) and 80 mg

23 tatin 80 mg group and in 148 of 4,418 in the atorvastatin 10 mg and simvastatin 20 to 40 mg groups (3

24 statin was shown), all patients were offered atorvastatin 10 mg daily open label.

25 treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a random

26 borative Atorvastatin Diabetes Study (CARDS; atorvastatin 10 mg versus placebo) of 3878 and 2838 pati

27 an Cardiac Outcomes Trial (ASCOT-LLA) study (atorvastatin 10 mg versus placebo) were used for model d

28 gh-dose statins (n = 83), were randomized to atorvastatin 10 versus 80 mg in a double-blind, multicen

29 y randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastat

30 r matching placebo; 10 mg TA-8995 plus 20 mg atorvastatin; 10 mg TA-8995 plus 10 mg rosuvastatin or 2

31 tal vein ligation/PPVL) rats received either atorvastatin (15 mg/kg; 7d) or control chow before sacri

32 Culturing islets with atorvastatin (15 uM) for 24 hours decreased glucose-stim

33 olesterol was lower in patients treated with atorvastatin (2.4 [0.07] vs. 2.6 [0.06] mmol/L; P = 0.00

34 (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg).

35 astatin 80 mg), 28.6% moderate-dose statins (atorvastatin 20-<40 mg, rosuvastatin 10-<20 mg, simvasta

36 with severe sepsis were administrated either atorvastatin (20 mg daily) or matched placebo.

37 not initially receiving a statin were given atorvastatin, 20 mg, and the following LLT intensificati

38 bed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%)

39 Simvastatin 40 mg and atorvastatin 40 mg accounted for 23.1% and 22.8% of all

40 s for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of m

41 th an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about pound2 per month

42 red in-hospital and after 4 weeks, on top of atorvastatin 40 mg.

43 d a randomized placebo-controlled trial with atorvastatin 40 mg/day for 9 weeks in 14 SPG5 patients w

44 High-intensity statins included atorvastatin 40 or 80 mg and rosuvastatin 20 or 40 mg.

45 High-intensity statins included atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, and

46 participants were taking high dose statins (atorvastatin 40-80 mg or rosuvastatin 20 mg), and low/me

47 Overall, 58.4% received high-dose statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg, simvastati

48 Atorvastatin (40 mg per day orally) was administered to

49 f tacrolimus, short-course methotrexate, and atorvastatin (40 mg per day orally).

50 filled a high-intensity statin prescription (atorvastatin, 40-80 mg, and rosuvastatin, 20-40 mg) with

51 enal and urinary AEs among patients assigned atorvastatin (481 [1.87%] per annum vs 392 [1.51%] per a

52 1.6+/-2.6% among those who received 10 mg of atorvastatin, 56.8+/-5.3% among those who received 80 mg

53 was significantly reduced from baseline with atorvastatin 80 mg (% reduction [95% confidence interval

54 meta-analysis, compared to the placebo, only atorvastatin 80 mg daily and atorvastatin and rosuvastat

55 MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS

56 patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months.

57 OD developed in 142 of 4,407 patients in the atorvastatin 80 mg group and in 148 of 4,418 in the ator

58 actors, NOD developed in 448 of 3,128 in the atorvastatin 80 mg group and in 368 of 3,103 in the lowe

59 group versus 63 (57%) of 110 patients in the atorvastatin 80 mg group; renal events occurred in nine

60 of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.

61 In this analysis, atorvastatin 80 mg lowered UPCR significantly more than

62 r filtration rate, and treatment status (ie, atorvastatin 80 mg or 10 mg).

63 pacity, and muscle strength before and after atorvastatin 80 mg or placebo was administered for 6 mon

64 Atorvastatin 80 mg resulted in significant additional re

65 ontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (DeltaTBR 80 mg vs. 10 mg g

66 taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-bl

67 io was 0.87 (95% CI 0.77-0.99; p=0.033) with atorvastatin 80 mg, 1.02 (0.88-1.18; p=0.83) with rosuva

68 We randomly assigned participants to atorvastatin 80 mg, rosuvastatin 10 mg, or rosuvastatin

69 Compared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of

70 ts, SD and ASV were significantly lower with atorvastatin 80 mg/day versus 10 mg/day (SD: 12.03 +/- 9

71 Targets) trial, randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at leas

72 Subanalysis of a randomized study of atorvastatin 80 mg/day versus pravastatin 40 mg/day for

73 10 mg, 124 to rosuvastatin 40 mg, and 111 to atorvastatin 80 mg; of these, 325 were included in the i

74 d a 2-by-2 factorial trial of the effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (

75 ndomly allocated to receive either high-dose atorvastatin (80 mg) or a placebo, given orally once a d

76 , or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin.

77 ification steps were applied: uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on al

78 a heterogeneous response to the treatment of atorvastatin; a significant fraction of, but not all, th

79 first to demonstrate in vivo that long-term atorvastatin administration alters cardiac ultrastructur

80 A novel two-pronged strategy of atorvastatin administration in both donors and recipient

81 Atorvastatin administration in healthy donors and recipi

82 Compared with baseline, atorvastatin administration in sibling donors was associ

83 ression, and used pharmaceutical inhibitors, atorvastatin, alendronate or zaragozic acid to inhibit t

84 The treatment of ezetimibe or atorvastatin alone decreased effectively the deposition

85 cholesterol than that attained with 80 mg of atorvastatin alone.

86 The structurally unrelated atorvastatin also hyperpolarized mitochondria in HepG2 c

87 Atorvastatin also increased average creatine kinase, sug

88 ike mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating stat

89 those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all com

90 19 patients were assigned to atorvastatin and 21 to placebo.

91 49 participants assigned to torcetrapib plus atorvastatin and 223 participants assigned to atorvastat

92 Of 420 patients, 194 received atorvastatin and 226 pravastatin; the median low-density

93 30 individuals were assigned atorvastatin and 30 were allocated placebo.

94 Modulation of CQ-induced cell death by atorvastatin and cholesterol is reproduced across numero

95 HLA-mismatched mouse cardiac transplant with atorvastatin and dasatinib and showed reduction of the C

96 ature suggested that two FDA-approved drugs (atorvastatin and dasatinib), approved for nontransplant

97 Atorvastatin and evolocumab independently accelerated th

98 Atorvastatin and fluvastatin were associated with the mo

99 At nontoxic doses, atorvastatin and mevastatin were unable to inhibit Mtb g

100 r placebo daily for 16 weeks, in addition to atorvastatin and other established therapies.

101 ncentrations (primary end point) between the atorvastatin and placebo groups (P = 0.76) and no intera

102 gment of the aorta was not different between atorvastatin and placebo, but technically adequate resul

103 When male mice underwent atorvastatin and pravastatin administration per os for u

104 We also found that atorvastatin and pravastatin each reduced systemic leuko

105 rdiac ventricular myocytes were treated with atorvastatin and pravastatin for 48 h.

106 ns mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.

107 RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local and vascu

108 Atorvastatin and pravastatin produced significant reduct

109 ipoprotein change was -53.3% and -28.3% with atorvastatin and pravastatin, respectively (p < 0.001).

110 Mechanistically, atorvastatin and rapamycin activated a protein kinase Ca

111 ynergy was reproduced in vivo, in which only atorvastatin and rapamycin therapy in combination was su

112 e placebo, only atorvastatin 80 mg daily and atorvastatin and rosuvastatin at doses equivalent to sim

113 genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; furth

114 Atorvastatin and rosuvastatin provided net benefit at lo

115 dds of discontinuations with higher doses of atorvastatin and rosuvastatin.

116 The actions of atorvastatin and RvTs were additive in E. coli infection

117 dontitis groups (n = 90), systemic and local atorvastatin and saline were administered in three diffe

118 e high sucrose fed animals were treated with atorvastatin and simvastatin, the two most prescribed st

119 6.8+/-5.3% among those who received 80 mg of atorvastatin, and 48.5+/-5.2% among those who received a

120 y 68.2% in patients given 10 mg TA-8995 plus atorvastatin, and by 63.3% in patients given rosuvastati

121 ins of R. oryzae were exposed to lovastatin, atorvastatin, and simvastatin and the minimum inhibitory

122 Black-box warnings, generic availability of atorvastatin, and updated guidelines may have resulted i

123 by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin.

124 -9 immunoreactivity, with systemic and local atorvastatin application during and after induction of e

125 e first time, the role of systemic and local atorvastatin application on periodontium using histomorp

126 Systemic and local atorvastatin application showed beneficial effects on pe

127 Local atorvastatin application showed better results on period

128 rived risk increased in the torcetrapib plus atorvastatin arm compared with the atorvastatin-only arm

129 were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Redu

130 owering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a

131 y, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at

132 plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin a

133 Components of the polypill were atorvastatin (at a dose of 10 mg), amlodipine (2.5 mg),

134 We conducted a comparative evaluation of Atorvastatin (AT) versus the non-statin cholesterol-lowe

135 to determine the effects of a model statin, atorvastatin (ATO), on the proliferation and differentia

136 tions to a greater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotec

137 reatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks.

138 Rosuvastatin (RSV) and atorvastatin (ATV) are known to inhibit osteoclastic bon

139 s designed to evaluate effectiveness of 1.2% atorvastatin (ATV) gel, as an adjunct to scaling and roo

140 Atorvastatin (ATV) has shown pleiotropic effects on bone

141 Rosuvastatin (RSV) and atorvastatin (ATV) have shown bone stimulatory and anti-

142 Atorvastatin (ATV) is a specific competitive inhibitor o

143 contains substantial cholesterol, we applied atorvastatin (ATV) to Madin-Darby Canine Kidney cells be

144 second-generation platelet concentrate, and atorvastatin (ATV), a potent member of the statin group,

145 eased hs-CRP level were randomly assigned to atorvastatin-based standard medical therapy or standard

146 ol lowering abilities, with rosuvastatin and atorvastatin being the most effective, while statins lik

147 Moreover, atorvastatin blocked the non-canonical Hh-pathway RhoA d

148 identify patients having symptoms only with atorvastatin but not placebo.

149 occurred in 209 of 491 (42.6%) while taking atorvastatin but not while taking placebo.

150 of muscle strength or exercise capacity with atorvastatin, but more atorvastatin than placebo subject

151 Atorvastatin, but not placebo, reduced serum 27-hydroxyc

152 ration per os for up to 7 mo, only long-term atorvastatin, but not pravastatin, induced elevated seru

153 Atorvastatin, but not pravastatin, inhibits cardiac Akt/

154 In cardiomyocyte-equivalent HL-1 cells, atorvastatin, but not pravastatin, reduced mitochondrial

155 change from baseline was significant in the atorvastatin, but not the pravastatin group (p < 0.001 a

156 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent

157 t 70 mg/dL and by statin intensity (maximal: atorvastatin calcium, 80 mg/d, or rosuvastatin, 40 mg/d;

158 ormalized photodegradation rate constants of atorvastatin, carbamazepine, and venlafaxine, which reac

159 prehensive metric to capture the totality of atorvastatin clinical efficacy in reducing disease burde

160 ients who were randomized to the addition of atorvastatin compared with those who were switched from

161 Atorvastatin concentration was associated with SLCO1B1 c

162 Atorvastatin consistently significantly reduced all-caus

163 randomised controlled trial to establish if atorvastatin could reduce cough in patients with bronchi

164 astatin the morning of surgery, and 40 mg of atorvastatin daily following surgery (n = 102) or matchi

165 Atorvastatin decreased cell-autonomous insulin-stimulate

166 Atorvastatin decreased portal pressure, shunt flow and a

167 Evolocumab but not atorvastatin decreased the production rate of intermedia

168 gions could be assessed in only 21 patients (atorvastatin Delta -0.03, 95% CI -0.17 to 0.12, vs place

169 ) atorvastatin group (NSPT plus medicated 2% atorvastatin dentifrice) and 2) placebo group (NSPT plus

170 to influence the degree of damage caused by atorvastatin depending on its interaction with CDC: Prep

171 n 40 mg versus usual care) and Collaborative Atorvastatin Diabetes Study (CARDS; atorvastatin 10 mg v

172 as significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromyci

173 NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone;

174 Intravenous administration of atorvastatin during MI limits cardiac damage, improves c

175 rms (A): A1 received an intravenous bolus of atorvastatin during MI; A2 received an intravenous bolus

176 Atorvastatin exerted a profound antioxidative effect on

177 Atorvastatin exerted significant antiatherogenic effects

178 cumulation and oxidation of vascular lipids, atorvastatin expedited the clearance of vascular lipids.

179 These results indicate that high-dose atorvastatin for 6 months does not decrease average musc

180 A1 and A3 remained on daily oral atorvastatin for the following 42 days.

181 l was performed with two parallel groups: 1) atorvastatin group (NSPT plus medicated 2% atorvastatin

182 t and 390 fewer total vascular events in the atorvastatin group (total events hazard ratio: 0.68; 95%

183 patients in this analysis (5101 [50%] in the atorvastatin group and 5079 [50%] in the placebo group),

184 f sites with CAL >/=5 mm, BOP, and GI in the atorvastatin group compared with the placebo group.

185 isk plaques was significantly reduced in the atorvastatin group compared with the placebo group: chan

186 12 (40%) of 30 patients in the atorvastatin group improved by 1.3 units or more on the

187 In the atorvastatin group of MIRACL, short-term risk increased

188 The atorvastatin group showed a decrease of 297.63 mm(2) in

189 9), AKI occurred in 22 of 102 (21.6%) in the atorvastatin group vs 13 of 97 (13.4%) in the placebo gr

190 6), AKI occurred in 42 of 206 (20.4%) in the atorvastatin group vs 47 of 210 (22.4%) in the placebo g

191 5), AKI occurred in 64 of 308 (20.8%) in the atorvastatin group vs 60 of 307 (19.5%) in the placebo g

192 90th percentile, -0.11 to 0.56 mg/dL) in the atorvastatin group vs by a median of 0.05 mg/dL (10th-90

193 f 36 individuals participated in this study (atorvastatin group, n = 18; placebo group, n = 18).

194 Ten (33%) patients assigned atorvastatin had an adverse event versus three (10%) all

195 educed total and ABCA1-specific CEC, whereas atorvastatin had no significant effect.

196 n patients receiving 10 mg TA-8995 and 20 mg atorvastatin HDL cholesterol levels increased by 152.1%

197 a four-component polypill including aspirin, atorvastatin, hydrochlorothiazide, and either enalapril

198 6 months of atorvastatin improved cough on a quality-of-life scale i

199 Nuclear activity of FXR was reduced by atorvastatin in a mouse FXR reporter assay.

200 ectiveness of a dentifrice medicated with 2% atorvastatin in improving clinical periodontal parameter

201 eline IL-6 concentration and continuation of atorvastatin in this cohort was associated with improved

202 n) or antiepileptogenic affect (for example, atorvastatin) in recognised rodent models or patients.

203 rocess was applied to a concise synthesis of atorvastatin, in which the key 1,6-boration was performe

204 Here we report that high dose atorvastatin increased the phagocytic function of ARPE-1

205 flow and angiogenesis in cirrhosis, whereas atorvastatin increased these parameters in PPVL rats.

206 The atorvastatin-induced decrease in insulin release was als

207 endoplasmic reticular (ER) stress, but only atorvastatin inhibited ERK1/2(T202/Y204), Akt(Ser473), a

208 Atorvastatin inhibited the non-canonical Hh-pathway and

209 In conclusion, atorvastatin inhibits insulin release and prevents posit

210 Atorvastatin is a potent immunomodulatory agent that hol

211 lesions of hypercholesterolemic zebrafish by atorvastatin is notably consistent with the known pharma

212 Atorvastatin (Lipitor) impaired insulin signaling in adi

213 y-dependent manner between 2 common statins: atorvastatin (lipophilic) and pravastatin (hydrophilic).

214 10 and December 2019 for statins, including, atorvastatin, lovastatin, pravastatin, rosuvastatin, and

215 Whereas evolocumab but not atorvastatin lowered the concentration of free PCSK9, at

216 tin lowered the concentration of free PCSK9, atorvastatin lowered the lathosterol/campesterol ratio (

217 atin 40-<80 mg), and 12.9% low-dose statins (atorvastatin <20 mg, rosuvastatin <10 mg, simvastatin <4

218 We found that chronic treatment with atorvastatin made the animals hyperglycemic and glucose

219 NSPT plus 2% atorvastatin medicated dentifrice was more effective in

220 Mean change in FIB-4 score with atorvastatin (n = 944) and fluvastatin (n = 34) was -0.1

221 (4D) who were randomized to either 20 mg of atorvastatin (n=519) or placebo (n=511).

222 double-blind trial to evaluate the impact of atorvastatin on arterial inflammation.

223 e further validated the beneficial effect of atorvastatin on graft survival by retrospective analysis

224 torvastatin and 223 participants assigned to atorvastatin only.

225 apib plus atorvastatin arm compared with the atorvastatin-only arm by 1.08% (P=0.0004).

226 mg TA-8995 plus 10 mg rosuvastatin or 20 mg atorvastatin or 10 mg rosuvastatin alone.

227 of the cholesterol biosynthesis pathway with atorvastatin or 25-hydroxycholesterol during switching f

228 rolemia, adding SAR236553 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a sign

229 Myalgic subjects on atorvastatin or placebo had decreased muscle strength in

230 se A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symp

231 y assigned (1:1) to 1 year of treatment with atorvastatin or placebo.

232 ar rate by participants randomly assigned to atorvastatin or placebo.

233 Intervention with aspirin, atorvastatin or renin-angiotensin system (RAS) inhibitor

234 e metabolic syndrome, current treatment with atorvastatin or rosuvastatin or simvastatin, hepatitis C

235 In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruite

236 evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or witho

237 nthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients only) when added to statin therapi

238 reduction was significant in patients using atorvastatin, pravastatin, and simvastatin.

239 Structurally, atorvastatin promoted favorable venous limb outward remo

240 load and a short-term reload with high-dose atorvastatin protects against early ischemic cerebral ev

241 ac Outcomes Trial (ASCOT, n = 155), 12-month atorvastatin reduced circulating miR-122.

242 Atorvastatin reduced non-calcified coronary plaque volum

243 Atorvastatin reduced the first occurrence of stroke and

244 tertiles confirmed this effect modification: atorvastatin reduced the risk of reaching the primary en

245 High-dose atorvastatin reduces periodontal inflammation, suggestin

246 p=0.005; n=37) decreased significantly with atorvastatin relative to placebo.

247 d given 6 h before intervention and either a atorvastatin reload (n = 76; 80 mg + 40 mg initiating 12

248 % in the 300-mg group; p = 0.019) and in the atorvastatin reload arm (18.4% vs. 35.0% in the no stati

249 clopidogrel load and a short-term, high-dose atorvastatin reload would improve outcomes in clopidogre

250 Atorvastatin restricts the ability of influenza virus to

251 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a significantly greater reducti

252 y lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell

253 onstrated with three different statin drugs (atorvastatin, rosuvastatin, and fluvastatin).

254 dividual cholesterol absorption rate affects atorvastatin's effectiveness to reduce cardiovascular ri

255 ar Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasou

256 ater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotective effects f

257 lecular-structural imaging demonstrated that atorvastatin significantly reduced fibrin deposition at

258 nificantly lower among participants assigned atorvastatin than assigned placebo (149 [1.00% per annum

259 end of follow-up, EAT regressed more in the atorvastatin than in the pravastatin group (median, -3.3

260 xercise capacity with atorvastatin, but more atorvastatin than placebo subjects developed myalgia (19

261 der control conditions were less impaired by atorvastatin than preparations that were nonresponsive t

262 nt (n = 199) were randomly assigned 80 mg of atorvastatin the day before surgery, 40 mg of atorvastat

263 vastatin the morning of surgery and 40 mg of atorvastatin the morning after (n = 206) or matching pla

264 of surgery, were randomly assigned 80 mg of atorvastatin the morning of surgery and 40 mg of atorvas

265 torvastatin the day before surgery, 40 mg of atorvastatin the morning of surgery, and 40 mg of atorva

266 After 24-hour culture with atorvastatin, the ability of CDC (500 nM) to elevate [Ca

267 ntification of positional isomers of hydroxy-atorvastatins, the primary metabolites of the drug atorv

268 ascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol

269 Atorvastatin therapy in severe sepsis did not affect IL-

270 lar disease, who were treated with intensive atorvastatin therapy, received either anacetrapib 100 mg

271 After 6 months of atorvastatin therapy, the median LDL-C and CRP were redu

272 ldenafil and the HMG CoA reductase inhibitor atorvastatin to further reduce K-RAS expression, and to

273 sterol ratios, predicts the effectiveness of atorvastatin to reduce cardiovascular risk in hemodialys

274 ubsequent) vascular events and the effect of atorvastatin to reduce these events by vascular territor

275 imaging was performed on control (n = 9) or atorvastatin-treated mice (0.01% w/w, n = 9).

276 refore, reduced (99m)Tc-cAbVCAM1-5 uptake in atorvastatin-treated mice was successfully monitored non

277 ptake was significantly reduced in 35-wk-old atorvastatin-treated mice, as indicated by ex vivo gamma

278 strate in a randomized controlled trial that atorvastatin treatment can effectively lower 27-hydroxyc

279 ing cardiac surgery, high-dose perioperative atorvastatin treatment compared with placebo did not red

280 (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting [A

281 Moreover, atorvastatin treatment for 12 weeks reduced target-to-ba

282 vents per 100 participants were avoided with atorvastatin treatment.

283 d 9899 patients in this analysis (6409 [65%] atorvastatin users and 3490 [35%] non-users), with a med

284 an change of 1.5 units in patients allocated atorvastatin versus -0.7 units in those assigned placebo

285 elial cyclooxygenase-2 (COX-2), increased by atorvastatin via S-nitrosylation of COX-2 and reduced by

286 Furthermore, atorvastatin was able to block the induction of interleu

287 Atorvastatin was associated with a reduced risk of incid

288 Administration of atorvastatin was associated with plaque stabilization an

289 lar transport of the known OATP2B1 substrate atorvastatin was changed in the presence of hyperforin,

290 sive Reduction in Cholesterol Levels) trial, atorvastatin was compared with placebo in 4,731 particip

291 tal number of vascular events prevented with atorvastatin was more than twice the number of first eve

292 A similar response to atorvastatin was observed in mice and cultured murine he

293 termination of the trial because efficacy of atorvastatin was shown), all patients were offered atorv

294 ion term between tertiles and treatment with atorvastatin was significantly associated with the risk

295 Atorvastatin was the most commonly prescribed statin (73

296 rption appear to benefit from treatment with atorvastatin, whereas those with high absorption do not

297 mits of this study, it can be concluded that atorvastatin, which is used for hypercholesterolemia tre

298 reproduced by simvastatin, whereas combining atorvastatin with cyclosporine or mycophenolate in place

299 e, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly red

300 s of vehicle during MI; and A3 received oral atorvastatin within 2 h post-MI.